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noglycoside antibiotics by O-phosphorylation. It is important to understand the mechanism of
enzymes in order to ﬁnd efﬁcient drugs. Using rapid-mixing methods, we studied the transient
kinetics of aminoglycoside phosphotransferase(30)-IIIa. We show that an ADP-enzyme complex is
the main steady state intermediate. This intermediate interacts strongly with kanamycin A to form
an abortive complex that traps the enzyme in an inactive state. A good strategy to prevent the inac-
tivation of aminoglycosides would be to develop uncompetitive inhibitors that interact with this key
ADP-enzyme complex.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V.1. Introduction
Bacterial resistance to antibiotics is a major concern in medical
treatment. Bacteria have evolved several mechanisms to combat
antibiotics [1]; these are often enzyme systems that are expressed
upon antibiotic challenge. A strategy for combating bacterial anti-
biotic resistance is to develop drugs that inhibit speciﬁcally these
enzymes. This is not an easy matter: as pointed out by Duclert-
Savatier et al. [2], to evaluate the pharmacological or medical
importance of an enzyme, one must have a clear understanding
of its function and, especially, its reaction pathway and mechanism
of action. As an example, this understanding is important for the
rational design of inhibitors of enzymes such as the aminoglyco-
side transferases that certain bacteria produce to inactivate amino-
glycoside antibiotics [3]. Cornish-Bowden [4] proposed that
uncompetitive inhibitors, that is to say inhibitors that interact spe-al Societies. Published by Elsevier
osphotransferase(30)-IIIa (EC
beled with N-[2-(1-maleim-
nne).ciﬁcally with an intermediate on an enzyme reaction pathway, are
especially powerful inhibitors. Thus, he proposes that once the en-
zyme has started to turn over, such inhibitors have a catastrophic
effect on its activity.
The aminoglycosides are especially susceptible to bacterial
resistance. To protect them against this type of antibiotic, several
bacteria have evolved enzymes that lead to their inactivation by
chemical modiﬁcation such as N-acetylation, O-adenylation and,
in particular, O-phosphorylation [5–7].
Aminoglycoside phosphotransferase(30)-IIIa, APH(30)-IIIa, has a
broad antibiotic speciﬁcity and has been the subject of several
structural and steady state kinetic studies [8–12]. With kanamycin
A (KanA) and ATP as substrates, this enzyme catalyzes the reaction:
KanAþ ATP$ 30-phosphoKanAþ ADP
In a steady state study in which ADP production was followed
by an indirect method using coupled enzyme system, McKay and
Wright [10,11] proposed that on the reaction pathway of
APH(30)-IIIa, 30-phosphoKanA is released rapidly followed by a
slow release of ADP with kinetics that limit the overall reaction.
Here, we tested this hypothesis by a transient kinetic study on
APH(30)-IIIa. We exploited two methods: rapid quench ﬂow byB.V. Open access under CC BY license.
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time scale [13] and stopped ﬂow which allows reactions to be fol-
lowed continuously by optical methods [14]. We show unambigu-
ously that ADP release is the rate limiting step of the reaction
pathway and that KanA is at once a substrate and a powerful inhib-
itor because it interacts with the intermediate EADP as well as
with the apoenzyme.
2. Materials and methods
2.1. Materials
KanA sulphate, ADP, ATP (BioXtra), phospho(enol)pyruvic acid
and pyruvate kinase/lactic dehydrogenase enzymes from rabbit
muscle were from Sigma–Aldrich. NADH was from Roche. Recom-
binant APH(30)-IIIa from Enterococcus faecalis was produced in
Escherichia coli BL21 (DE3) transformed with pET15b plasmid
encoding for APH(30)-IIIa with a 6His-tag in N-terminal (from
E.H. Serpersu). Production and puriﬁcation procedures were as in
[15] except that the induction was at 20 C OVN. The fractions con-
taining APH(30)-IIIa were concentrated to 40–60 mg/ml in 20 mM
Tris–HCl pH 7.5, 100 mM NaCl, 1 mM DTT using an ultra-ﬁltration
device (Amicon Ultra-15, cutoff 10 kDa, Millipore). Aliquots of
99% pure protein were stored at 20 C with 50% glycerol and
10 mM DTT. The concentration of APH(30)-IIIa was determined
using an extinction coefﬁcient of 48735 M1 cm1 at 280 nm.
Except otherwise stated, in the text APH(30)-IIIa refers to the
6His-tagged recombinant APH(30)-IIIa. As a control, the removal
of the N-terminal 6His-tag was carried out by cleavage of the
tagged protein with thrombin as in [16]. The catalytic activity
was assayed and compared to that of fresh 6His-tagged APH(30)-
IIIa and of the protein handle in the same way as the one cleaved
(except the presence of thrombin). The 6His-tag and the presence
of sulphate at 0.2 mM (KanA sulphate used) had no effect on the
steady state rates (not shown).
2.2. Experimental conditions
Experiments were carried out at 25 C and in a buffer containing
50 mM Tris–HCl pH 7.5, 40 mM KCl and 1 mM free MgCl2. The con-
centration of free Mg2+ used was 1 mM and not 10 mM as in main
studies with APH(30)-IIIa because 1 mM is rarely inhibitory with ki-
nases and is probably close to the in vivo level [17]. Equimolar con-
centration of MgCl2 was added with ADP and ATP. In the text, ADP
and ATP refer to MgADP and MgATP, respectively. The concentra-
tions of reactants given refer to the ﬁnal reaction mixture
concentrations.
2.3. ADP measurements and transient kinetic methods
The time courses of ADP production were obtained by three
methods.
The quench ﬂow method [13,18] is essentially a chemical sam-
pling method on the time scale of milliseconds to several seconds.
The experiments were carried out in a thermostated beaker or a
QFM-400 (Bio-Logic, France) thermostatically controlled equip-
ment. APH(30)-IIIa, pre-incubated with KanA, was mixed with
ATP in the apparatus, the reaction mixtures aged for speciﬁc times,
quenched in acid (10% perchloric acid) and ADP measured by HPLC
as in [19]. By this method, the total concentrations of ADP, that is
to say enzyme-bound as well as free ADP, were obtained.
In the coupled assay method of McKay and Wright [10], free ADP
production was measured as NADH consumption by coupling the
APH reaction to the pyruvate kinase/lactate dehydrogenase sys-
tem. Experiments were carried out in a thermostatically controlled
SF-61 DX2 stopped ﬂow apparatus (TgK Scientiﬁc, UK). APH(30)-IIIapre-incubated with KanA (or ATP), 140 lM NADH, 2 mM
phospho(enol)pyruvate, 16 U/ml pyruvate kinase and 23 U/ml lac-
tate dehydrogenase was mixed with ATP (or KanA) in the appara-
tus and the absorbance at 340 nm was measured as a function of
time. The concentration of NADH was determined using an extinc-
tion coefﬁcient of 6220 M1 cm1 at 340 nm.
In the ADP biosensor method, free ADP was measured by the use
of an engineered bacterial actin homologue labelled with a single
coumarin ﬂuorophore, MDCC-ParM [20]. Fluorescence stopped
ﬂow experiments were carried out as in [15]. The excitation wave-
length was 436 nm and the emission wavelength was >455 nm
using a cut-off ﬁlter. The excitation and emission slits were 2 nm.
APH(30)-IIIa, pre-incubated with 100 lM KanA, was mixed in the
apparatus with ATP and 30 lM MDCC-ParM and the ﬂuorescence
was measured as a function of time. The background signal coming
from ATP binding to MDCC-ParM was corrected for by measuring
the background ﬂuorescence time course by mixing the same solu-
tions but without KanA. The concentration of free ADP was deter-
mined by measuring the total ﬂuorescence change (at the end of
the reaction), assuming that all ATP has been converted to ADP
(see below) that is then trapped by MDCC-ParM [20].
3. Results
3.1. Steady state experiments
A comparison of the steady state time courses of ADP produc-
tion measured by the coupled assay and the quench ﬂow methods
is shown in Fig. 1. Whereas the time course obtained by the cou-
pled assay method is linear over 500 s (Fig. 1A), that obtained by
the quench ﬂow method is not, and only the very initial portion
(Fig. 1B) was used to obtain the steady state rate (kss). The initial
kss determined by the two methods were identical:
0.55 ± 0.02 s1 by quench ﬂow, 0.54 ± 0.01 s1 by stopped ﬂow.
The order of mixing of APH with the two substrates had no effect
on kss: 0.54 ± 0.01 s1 when pre-incubating APH with KanA and
then mixing with ATP compared to 0.53 ± 0.01 s1 when pre-incu-
bating APH with ATP and mixing with KanA (black line and grey
line respectively in Fig. 1B). This suggests that kss is not limited
by the binding of substrates.
The non-linearity of the quench ﬂow time course is almost cer-
tainly due to the accumulation of ADP that may compete with ATP
for the binding to the active site. In the coupled assay method, the
ADP is removed as soon as it is formed and converted back to ATP
by pyruvate kinase. We conclude that whereas the chemical sam-
pling method is simpler, more direct and more ﬂexible than the
linked enzyme assay method, which does not allow for transient
kinetic studies, care must be taken to consider only the initial time
course.
To conﬁrm this, we carried out steady state measurements by
the quench ﬂow method (which measures total ADP) in the pres-
ence or not of 30 lMMDCC-ParM, an ADP biosensor [20] that traps
the free ADP as soon as it is released. At this concentration of
MDCC-ParM, binding of ADP is fast and tight, as the Kd is <1 lM
[20]. Because MDCC-ParM has to be in excess compared to the
ADP produced by the APH catalysed reaction, this experiment
was done at relatively low ATP concentration (20 lM). As a com-
parison, the experiment was carried out in the same conditions
in a stopped ﬂow apparatus, using the coupled assay method.
The time courses obtained are shown in Fig. 2. Again, the time
course obtained by the coupled assay method is linear, but that ob-
tained by the quench ﬂow method is not. This non-linearity may
result either from the inhibition of the reaction by the ADP released
or by the decrease of ATP concentration below the Km (10 lM, data
not shown). Removing the free ADP by MDCC-ParM signiﬁcantly
increases the duration of the initial linear portion of the time
Time (s)
0 10 20 30 40
[A
D
P]
/[A
PH
] (m
o
l/m
ol)
0
5
10
15
20
[AD
P] (µM)
0
1
2
3
4
Time (s)
0 100 200 300 400 500
[A
D
P]
/[A
PH
] (m
o
l/m
ol)
0
50
100
150
200
[AD
P] (µM)
0
10
20
30
40A
B
Fig. 1. Steady state time courses of ADP production measured by the coupled assay
(absorbance stopped ﬂow) and the quench ﬂow methods on two different time
scales: 500 s (A) and 40 s (B). The reaction mixtures were 0.2 lMAPH, 100 lMKanA
and 200 lM ATP. Stopped ﬂow traces are shown as continuous lines and quench
ﬂow as circles. In B, stopped ﬂow traces were obtained either by mixing APH and
KanA with ATP (black line) or APH and ATP with KanA (grey line). In quench ﬂow,
APH was pre-incubated with KanA and mixed with ATP in the apparatus. The ﬁtting
of the linear portion of the quench ﬂow time course is shown as a dashed line.
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Fig. 2. Steady state time courses of ADP production measured by the coupled assay
(absorbance stopped ﬂow, continuous line) and the quench ﬂow methods in the
absence (circle) or presence (squares) of 30 lM MDCC-ParM. Time courses are
shown on two different time scales: 30 min (A) or 400 s (B). The reaction mixtures
were 0.5 lM APH, 100 lM KanA and 20 lM ATP.
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Fig. 3. Transient time courses of free and total ADP production measured by the
ADP biosensor (ﬂuorescence stopped ﬂow) and the quench ﬂow methods. The
reaction mixtures were 5 lM APH, 100 lM KanA and 20 lM ATP, plus 30 lM
MDCC-ParM in the ﬂuorescence stopped ﬂow experiment. The stopped ﬂow trace is
shown as a continuous line and the quench ﬂow as circles with a single exponential
plus linear ﬁt as a dashed line.
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depletion of ATP.
With the three methods, the reaction appears to go to comple-
tion (Fig. 2A) which shows that the overall forward reaction of
APH(30)-IIIa is virtually irreversible. In the quench ﬂow experi-
ments, the ﬁnal plateau corresponds to all ATP being converted
into ADP (20 lM). In the coupled system experiment, the ATP is
constantly regenerated from ADP and therefore the reaction stops
when all KanA has been used (100 lM).
3.2. Transient kinetics of ADP formation
Both APH(30)-Ia and APH(30)-IIa have signiﬁcant ATPase activi-
ties [21]. Whereas in 1996, McKay and Wright [11] found that
APH(30)-IIIa had no ATPase activity, earlier in the same group
[22] and in our hands it had. In our conditions and at 20 lM ATP,
the ATPase steady state rate was 0.0017 s1 which is 0.66% of the
kinase activity at the same concentration of ATP (not shown).
Whereas this low activity had little effect on the steady state kinet-
ics, it precluded transient kinetic experiments (that is to say at high
enzyme concentrations) in which APH(30)-IIIa is mixed with ATP
before KanA.
Two typical time courses of ADP formation with resolution in
the milliseconds range are illustrated in Fig. 3. The total ADP time
course was obtained by the rapid quench ﬂow method and it
shows a transient burst of ADP formation, followed by a linear rise
in ADP. This burst suggests that ADP, free or enzyme-bound, accu-
mulates before the steady state is reached. The time course ﬁts toan exponential phase of rate constant kburst = 7.1 ± 1.4 s1 and
amplitude Aburst = 0.64 ± 0.06 mol ADP/mol enzyme, that is fol-
lowed by the steady state of rate constant kss = 0.31 ± 0.04 s1.
When the enzyme on its own was mixed with KanA and ATP to-
gether, the time course of total ADP was identical to that in
Fig. 3 (time course not illustrated).
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free ADP, we studied the reaction by using the ADP biosensor [20] to
measure the kinetics of ADP release. The free ADP time course was
obtained by ﬂuorescence stopped ﬂow (Fig. 3). This shows a lag fol-
lowedbya linear rise in freeADP.The linearpart (from1 s)ﬁtswell to
a straight line that represents kss = 0.37 ± 0.01 s1, which is in good
agreement with the 0.31 s1 estimated by the quench ﬂowmethod.
The intercept of the linear ﬁtwith theX axis gives an estimate for the
duration of the lag phase of 430 ms. The absence of a burst of free
ADP shows that the total ADP burst obtained by the rapid quench
ﬂow method is due to enzyme-bound ADP. It other words, ADP re-
lease is the rate limiting step of the reaction pathway. The transient
lag phase preceding the steady state in the ﬂuorescence time course
is presumably the manifestation of the time required for the forma-
tion of enzyme-bound ADP.
3.3. Effect of added ADP on the APH(30)-IIIa reaction
As illustrated in Fig. 4, three quench-ﬂow experiments were
carried out. Fig. 4A represents the control experiment, that is to
say a time course in the absence of added ADP (also see Fig. 3).
In Fig. 4B, the ATP had been incubated with equimolar concentra-
tion of ADP before mixing with APH and KanA. This gives a timecourse with Aburst = 0.29 ± 0.05 mol/mol, kburst = 7.1 ± 2.9 s1 and
kss = 0.15 ± 0.03 s1. We explain the 50% reduction of both Aburst
and kss by the competition between ADP and ATP for the binding
to EKanA. The enzyme in the abortive EKanAADP complex cannot
turn over on the time scale of the transient burst because the re-
quired release of ADP is slow (see below). The remaining portion
of enzyme appears to be fully active because the kburst obtained
is close to that in the absence of added ADP.
In Fig. 4C, the EKanA complex had been pre-incubated with
ADP before mixing with ATP. We underline that the concentrations
in the ﬁnal reaction mixtures were identical to those in Fig. 4B.
Thus, the steady state rates were similar (0.15 ± 0.03 s1 in
Fig. 4B and 0.17 ± 0.02 s1 in Fig. 4C). However, the mixing of
EKanA with ADP before ATP has a catastrophic effect on the pre-
steady state kinetics: there was no sign of a transient burst phase
of ADP. This is evidence that at this concentration of ADP in the
pre-incubation mixture, all enzyme is trapped in the abortive
EKanAADP complex, compared to half in the previous experiment.
4. Discussion
As pointed out by Gutfreund [23], ‘‘rapid reaction techniques
are essential for the elucidation of the chemical mechanism of en-
P. Lallemand et al. / FEBS Letters 586 (2012) 4223–4227 4227zyme reactions’’ and, in particular, ‘‘the algebra of steady state
kinetics is no substitute for the direct observation of the formation
and decomposition of intermediates’’. Here, using pre-steady state
kinetics methods, we present direct chemical evidence that ADP
release is the rate limiting step on the reaction pathway of
APH(30)-IIIa. APH(30)-Ia and -IIa have also been subject to a pre-
steady state study with KanA as the substrate [21,24]. With each
enzyme, there was a large transient burst phase of phosphoKanA
but the state of the phosphoKanA (free or protein-bound) was
not determined.
Further, we show that in the presence of 100 lM KanA, ADP is a
powerful inhibitor of APH(30)-IIIa. In our pre-steady state kinetic
study, the decrease of 50% of the ADP burst amplitude and of the
steady state rate (Fig. 4A and B) when the same concentration of
ADP was added to ATP, suggests that in the presence of KanA,
ADP binds to APH(30)-IIIa with an afﬁnity similar to that of ATP.
Taken together, our results support the proposals of McKay and
co-workers [10,22] that the release of ADP occurs from a binary
EADP complex. However, these proposals were based upon steady
state kinetics only, and further, on the use of a coupled enzyme
system which perturbs the equilibrium of the APH reaction by
removing only one of the products. For this reason, McKay and
Wright could not detect the APH(30)-IIIa inhibition by ADP. The
intermediate EADP binds tightly KanA and we show that the
ADP is released slowly from the ternary EADPKanA complex.
Cornish-Bowden [4] pointed out that a promising strategy in
drug design that involves enzymes is to work on uncompetitive
rather than the less efﬁcient competitive inhibitors. Here, with
APH(30)-IIIa, the reaction intermediate EADP seems to be a good
target to develop drugs to inhibit an enzyme that is responsible
for the resistance of bacteria to several aminoglycoside antibiotics.
Release of ADP is rate limiting, so that a screening assay which
tests compounds that reduce the steady state ATPase might be use-
ful for looking for such drugs that bind to EADP. As pointed out by
Ejim et al. [25], an approach to this end is to combine an antibiotic
with a non-antibiotic drug that enhances antibacterial efﬁcacy. To
extend the arguments of Cornish-Bowden, we suggest that the
non-antibiotic drug should be an uncompetitive inhibitor.
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